4528
ONO PHARMACEUTICAL CO.,LTD.
小野薬品工業
- Industry
- Pharmaceutical
- Market
- Prime
- Accounting standards
- IFRS
- Consolidation basis
- Consolidated
Key metrics
Revenue(million JPY)
Mar 2021
309,284
Mar 2022
361,361
Mar 2023
447,187
Mar 2024
502,672
Mar 2025
486,871
Operating profit(million JPY)
Mar 2021
98,330
Mar 2022
103,195
Mar 2023
141,963
Mar 2024
159,935
Mar 2025
59,747
Operating profit margin(%)
Mar 2021
31.79
Mar 2022
28.56
Mar 2023
31.75
Mar 2024
31.82
Mar 2025
12.27
Profit before tax(million JPY)
Mar 2021
100,890
Mar 2022
105,025
Mar 2023
143,532
Mar 2024
163,734
Mar 2025
59,328
Profit(million JPY)
Mar 2021
75,425
Mar 2022
80,519
Mar 2023
112,723
Mar 2024
127,977
Mar 2025
50,047
Total assets(million JPY)
Mar 2021
746,842
Mar 2022
739,203
Mar 2023
882,437
Mar 2024
913,668
Mar 2025
1,064,046
Cash and cash equivalents(million JPY)
Mar 2021
61,045
Mar 2022
69,112
Mar 2023
96,135
Mar 2024
166,141
Mar 2025
204,567
Cash flows from operating activities(million JPY)
Mar 2021
73,977
Mar 2022
61,829
Mar 2023
159,610
Mar 2024
110,660
Mar 2025
82,459
Cash flows from investing activities(million JPY)
Mar 2021
-57,586
Mar 2022
6,038
Mar 2023
-100,259
Mar 2024
48,077
Mar 2025
-136,785
Cash flows from financing activities(million JPY)
Mar 2021
-24,754
Mar 2022
-60,237
Mar 2023
-32,484
Mar 2024
-89,848
Mar 2025
94,299
Return on equity(%)
Mar 2021
12.6
Mar 2022
12.5
Mar 2023
16.1
Mar 2024
16.7
Mar 2025
6.4
Equity ratio(%)
Mar 2021
85.1
Mar 2022
88.7
Mar 2023
84.1
Mar 2024
86.8
Mar 2025
73.5
Earnings per share(JPY per share)
Mar 2021
151.11
Mar 2022
162.19
Mar 2023
230.85
Mar 2024
266.61
Mar 2025
106.55
Net assets per share(JPY per share)
Mar 2021
1,273.28
Mar 2022
1,343.4
Mar 2023
1,519.19
Mar 2024
1,688.43
Mar 2025
1,665.61
Dividend per share(JPY per share)
Mar 2021
50
Mar 2022
56
Mar 2023
70
Mar 2024
80
Mar 2025
80
Payout ratio(%)
Mar 2021
33.09
Mar 2022
34.53
Mar 2023
30.32
Mar 2024
30.01
Mar 2025
75.08
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.